You are here: Industry Insights > CTLA-4

News List

China's First Domestic CTLA-4 Inhibitor, in Combination With Sintilimab as Neoadjuvant Treatment for Colon Cancer PR Newswire
February 24, 2025
NMPA Accepts NDA and Grants Priority Review Designation to combine with Sintilimab as Treatment for Colon Cancer.
HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021 prnasia
July 27, 2021
Harbour BioMed announced that the abstract detailing clinical data from its Australian phase I study of next-generation anti-CTLA-4 antibody in patients with advanced solid tumors will be presented as an e-poster at the 2021 European Society for ...
Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody prnasia
May 12, 2021
Harbour BioMed announced the dosing of the first patient in its part 2 of phase I (phase Ib/IIa) clinical study of its next-generation anti-CTLA-4 antibody, where Australian patients with metastatic or advanced melanoma, hepatocellular carcinoma (HCC) ...
Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors prnasia
September 22, 2020
Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company announced approval of two Investigational New Drug (IND) applications by the China National Medical Products Administration (NMPA) of its next-generation fully human ...
Agenus Commences Trial of Next-Gen CTLA-4 with PD-1 Antibody americanpharmaceuticalreview
December 20, 2019
Agenus announced the first patient dosed with AGEN1181, an anti-CTLA-4 antibody, in combination with balstilimab, Agenus' PD-1 inhibitor.
BioAtla & BeiGene Enter Development Pact contractpharma
April 15, 2019
Agreement also covers the manufacturing and commercialization of BioAtla’s investigational CAB CTLA-4 antibody (BA3071).